<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029470</url>
  </required_header>
  <id_info>
    <org_study_id>EMR700642-606</org_study_id>
    <nct_id>NCT01029470</nct_id>
  </id_info>
  <brief_title>To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation</brief_title>
  <official_title>A Multicentre, Prospective, Open Study to Describe the Effects of rhLH Supplement in Women With Hyporesponse to rFSH After Pituitary Downregulation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Health Center for Women and Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reproductive &amp; Genetic Hospital of CITIC-Xiangya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To evaluate the efficacy in terms of oocyte retrieval number of rLH supplement in women with
      hyporesponse to rFSH after pituitary downregulation.

      Secondary objective:

      To further explore the efficacy of rLH supplement in women with hyporesponse to rFSH after
      pituitary downregulation To evaluate the safety of rLH supplementation in hyporesponse women
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:

      Number of oocyte retrieved

      Secondary endpoints:

        1. Oestrodial on hCG day (pg/ml)

        2. Number of embryos

        3. Implantation rate (%)

        4. Clinical pregnancy rate (%)

        5. Ongoing PR per IVF cycle (%)

        6. Abortion rate (%)

        7. Ampoules of rFSH

        8. FertiQoL score Safety endpoint: adverse events
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocyte retrieved</measure>
    <time_frame>2009Dec-2010Oct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Oestrodial on hCG day (pg/ml) Safety: adverse events</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Number of embryos</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Implantation rate (%)</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Clinical pregnancy rate (%)</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Ongoing PR per IVF cycle (%)</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6. Abortion rate (%)</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7. Ampoules of rFSH</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8. FertiQoL score Safety: adverse events</measure>
    <time_frame>2009 Dec-2010 Oct</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Luveris</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luveris</intervention_name>
    <description>Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day</description>
    <arm_group_label>Luveris</arm_group_label>
    <other_name>Gonal-f, ovidrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20-40 years old women

          2. With menstrual cycles ranged 24-35 days, intraindividual variability±3 days

          3. Basal FSH &lt;10 IU/L at cycle D2-D5

          4. 18 &lt; BMI &lt; 30

          5. Presence of two ovaries

          6. No ovarian stimulation over the past 3 months

          7. Signed inform consent form.

        Exclusion Criteria:

          1. Polycystic ovarian syndrome

          2. rAFS stage Ⅲ-Ⅳ endometriosis

          3. Chromosomal abnormalities, endocrinological and/or autoimmune disorders.

          4. More than two previously unsuccessful IVF.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Qiao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Qiao, MD, PHD</last_name>
    <phone>86-10-82266699</phone>
    <email>qiaojiebu3h@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Qiao, MD, PHD</last_name>
      <phone>86-10-82266699</phone>
    </contact>
    <investigator>
      <last_name>Jie Qiao, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>December 9, 2009</last_update_submitted>
  <last_update_submitted_qc>December 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jie Qiao</name_title>
    <organization>Peking University Third Hospital Reproductive Medical Center</organization>
  </responsible_party>
  <keyword>Luveris</keyword>
  <keyword>hyporesponse</keyword>
  <keyword>pituitary downregulation</keyword>
  <keyword>IVF</keyword>
  <keyword>Infertility women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

